To this end, this study combines two important components that are intended to inform a future, more comprehensive evaluation plan:
- First, an evaluability and evaluation design component that should ultimately help ensure robust evaluation work to follow.
- Secondly, a baseline study that is intended to both inform potential course correction through early assessment of core design elements and to enable appropriate measurement over time of the effectiveness and performance of the COVAX Facility and COVAX AMC.
Scope of WorkBroader context: the ACT-A Vaccine Pillar
The Access to COVID-19 Tools – Accelerator (ACT-A), launched at the end of April 2020, brings together public and private expertise and institutions from around the world with a vision to create a global solution to expedite the end of the COVID-19 pandemic. It aims to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
The ACT-A is comprised of four technical partnerships: three vertical pillars (vaccines, therapeutics, and diagnostics) and one transversal health systems connector. The ACT-A partnerships include a broad and inclusive collaboration between diverse stakeholders, jointly leveraging their comparative advantages and respective constituencies to drive towards collective solutions to address COVID-19.
The COVAX Facility and the COVAX Advance Market Commitment (AMC)
The COVAX Facility and the COVAX AMC are instruments contributing to the delivery of the ACT-A Vaccines Pillar. The goals of COVAX are:
- To end the acute phase of the pandemic by end 2021
- To deliver 2 billion doses of COVID-19 vaccine by end 2021
- To guarantee fair and equitable access to COVID19 vaccines for all participating countries
- To support the largest actively managed portfolio of COVID-19 vaccine candidates globally
To offer a compelling return on investment by delivering COVID19 vaccines as quickly as possible
Objectives and scope of this assessmentThe scope of this RFP is focused on evaluability, a proposal for the design of COVAX Facility and COVAX AMC multi-stage evaluation (Evaluation), and a baseline study. The primary purpose of this evaluability, evaluation design and baseline study is to provide a foundation to help inform, steer and shape future evaluation related work to follow thereafter and to ensure a robust baseline is put in place. The primary purpose of this evaluability, evaluation design and baseline study is to provide a foundation to help inform, steer and shape future Evaluation related work to follow thereafter and to ensure a robust baseline is put in place. The baseline study, more specifically, is intended to both inform potential course correction through early assessment of core design elements and to enable appropriate measurement over time of the effectiveness and performance of the COVAX Facility and COVAX AMC.
The primary audience for this evaluability, evaluation design and baseline study is the Gavi Board, and all partners and countries who are contributing to the COVAX efforts.
It is important to note that the work to be commissioned in this RFP will be implemented in two phases: phase 1: evaluability and evaluation design; and phase 2: baseline study. While the expectation and intention are that the same bidder will complete both phases, the phase 2 baseline study component will only be given the green light based on satisfactory completion of phase 1: evaluability and evaluation design.
Two-Envelope SystemMembers of the Tender Evaluation Committee (TEC) will score each Proposal based on the weighted Technical Criteria listed below (Section 3.4.). Proposals will then be ranked according to their technical scores. Proposals that meet the required technical minimum shall then be progressed to the financial evaluation stage and an assessment based on the weighted Financial Criteria will be carried out. The TEC will then determine which Proposals to shortlist/select based on best value-for-money over the whole-of-life of the Contract.
Qualifying CriteriaEach Proposal must meet all of the following qualifying criteria. Proposals which fail to meet one or more will be excluded from further consideration.
Bidders who are unable to meet all the qualifying criteria should conclude that they will not benefit from submitting a Proposal. The qualifying criteria for this procurement are:
Corporate Social Responsibility
Bidders must provide a copy of their Corporate Social Responsibility Policy or documentation to demonstrate their commitment to sustainability, diversity, inclusion, and the environment.
Bidders must provide the past 3 (three) year Financial Statements: namely: Auditor’s page, Income/P&L, Balance Sheet & Cash Flow.
Bidders must be able to provide at least 3 reference contacts within their proposal. This should include the name of an organization, Point of Contact, email address and telephone number of the point of contacts and a summary of the services provided to the organization.
Intent to Participate, Acceptance of Confidentiality requirements and Conflict of Interest Declaration.
Bidders are required to acknowledge their acceptance of the RFP instructions and rules. Bidders are also required to provide the contract information for a representative who will be the point of contact for all matters relating to the RFP, no later than the Due Date for submission of Preliminary Information indicated in Part 1. Bidders are required to maintain confidentiality in all matters relating to this RFP and shall not disclose confidential information in connection with the RFP to any third party without prior written consent of Gavi.
Each Bidder must complete the Conflict-of-Interest declaration and must immediately inform Gavi should a Conflict of Interest arise during the RFP process. A Conflict of Interest may result in the Bidder being disqualified from participating further in the RFP. This declaration must be provided to Gavi no later than the Due Date for Preliminary Information set out in Part 1.
A high level debrief on a bids relative strengths and weaknesses can be requested by email to [email protected] with the subject line “042-2021-GAVI-RFP– Debrief – [Bidder Name]”.
The relative strengths and weaknesses of the bid can be discussed, however Gavi is under no obligation to share exact scores, rankings, or details of any other bid, including the winning bid.
Bidders must submit a copy of their Proposal to Gavi by email to: [email protected]
The subject heading of the email shall be “042-2021-GAVI-RFP– Technical Proposal – [Bidder Name]” and “042-2021- – Financial Proposal – [Bidder Name]”. Bidders may submit multiple emails (suitably annotated – e.g., Email 1 of 3) if the attached files are too large to suit a single email transmission.
Requests for Clarification
Bidders may submit requests for clarification of the solicitation documents and direct any questions regarding the RFP content or process to [email protected] using the subject line “042-2021-GAVI-RFP– Clarification – [Bidder Name]”
Please ensure that the different Proposal elements are returned in either MS Office Format or PDF.
- To help us track our procurement effort, please indicate in your email where (ngotenders.net) you saw this tender/procurement notice.